Suppr超能文献

纳米药物递药系统靶向治疗肝纤维化的研究进展。

Advances in the research of nanodrug delivery system for targeted treatment of liver fibrosis.

机构信息

Department of Biotechnology, Bengbu Medical College, Anhui 233030, China; Anhui Province Key Laboratory of Translational Cancer Research, Bengbu Medical College, Anhui 233030, China.

Department of Biotechnology, Bengbu Medical College, Anhui 233030, China.

出版信息

Biomed Pharmacother. 2021 May;137:111342. doi: 10.1016/j.biopha.2021.111342. Epub 2021 Feb 10.

Abstract

Liver fibrosis is one of the major threats to human health. At present, anti-liver fibrosis drugs exist some problems,such as, lack of targeting, limited treatment effect and more or less toxic side effects. In order to improve the efficacy of targeted therapy for liver fibrosis, the development of a large number of nanocarriers and strategies of targeted therapy for liver fibrosis have been widely studied. In this paper, the research progress of nano-delivery vectors targeting cells related to the process of liver fibrosis in recent years was reviewed in terms of targeting vectors and the types of modified ligands, providing a new strategy for targeted cell therapy and theoretical reference for the realization of high efficient targeted therapy of liver fibrosis.

摘要

肝纤维化是危害人类健康的主要因素之一。目前,抗肝纤维化药物存在靶向性不足、治疗效果有限、毒副作用或多或少等问题。为了提高肝纤维化靶向治疗的疗效,人们广泛研究了大量的纳米载体和肝纤维化靶向治疗策略。本文从靶向载体和修饰配体类型两个方面,对近年来针对肝纤维化发生过程中相关细胞的纳米递药载体的研究进展进行综述,为靶向细胞治疗提供新策略,为实现肝纤维化的高效靶向治疗提供理论参考。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验